Report Description of the Australia Dermatology Treatment Drugs Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Australia Dermatology Treatment Drugs Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Australia Dermatology Treatment Drugs Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

Australia Dermatology Treatment Drugs Market Analysis Executive Summary

Australia is one of the important and emerging markets for organic and natural personal care products. According to Australian research, more than 4% of the population are affected by acne vulgaris in long term. The growing inclination towards skin health and care among millennials can have an excellent impact on the market growth in the forthcoming years. The increasing R&D investments by major companies owing to heavy demand for therapeutically effectual and cost-effective drugs will encourage the healthy growth of the market in the foreseeable future.

Market Size and Key Findings

The Australia Dermatology Treatment Drugs Market Analysis size stood at around USD xx% billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

Skincares growth is attributable to the unique position it occupies amongst a variety of trends. The growing desire for health-promoting and self-care products, increasing interest in the power of regimens and routines, the ability of social media to more rapidly empower and inform consumers, and, uniquely, the ability of new technology to simplify the unusually complex choices consumers have when they interact with skincare brands. From artificial intelligence to 3D printing, augmented reality and DNA analysis, the beauty industry is becoming increasingly technology-driven. Personalization is a crucial area of development for beauty brands, tapping into consumer desire for products that can be customized to suit individual needs.

Market Restraints

Product recall of products having these drugs is expected to restraint the usage of dermatology drugs and is expected to slow down the growth of the dermatology drugs market in the forecasted period.

Covid-19 Market Impact Analysis

As the phase III COVID-19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVID-19 vaccination in dermatology patients on immunomodulatory and/or biologic agents.

• Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents.


• There are currently insufficient data to recommend one COVID-19 vaccine or vaccine type (mRNA, recombinant, inactivated virus) over another.


• No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified.


• Data on vaccine efficacy in patients on immunomodulatory or biologic therapies are missing, so standard vaccination protocols are recommended until otherwise advised.

Competitive Landscape

Key Players

The major players covered in the report are Novartis AG, Pfizer Inc., Eli Lilly and Company., Johnson & Johnson Services, Inc., Almirall, S.A, Mylan N.V., Sun Pharmaceutical Industries Ltd., UCB S.A., Belgium, Glenmark Pharmaceuticals Limited, Tolmar Pharmaceuticals, Inc., GlaxoSmithKline plc., Galderma Laboratories, L.P., Teva Pharmaceutical Industries Ltd., LEO Pharma A/S, MELINTA THERAPEUTICS, INC. - THE ANTIBIOTICS COMPANY, Mayne Pharma Group Limited, BIOFRONTERA AG, AbbVie Inc. among others.

Products in Pipeline

• This interim advice is for clinicians treating patients with severe inflammatory skin disorders managed on conventional and newer immunomodulators. This includes systemic corticosteroids, azathioprine, ciclosporin, methotrexate and mycophenolate mofetil/mycophenolic acid, as well as the newer biologics for eczema and psoriasis including anti-TNF (e.g. adalimumab, certolizumab, etanercept, infliximab), anti-IL4/13 (dupilumab), anti-IL12/23 (ustekinumab), anti-IL17/23 (guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab), and small molecules such as PDE inhibitors (apremilast) and JAK inhibitors (abrocitinib, baricitinib, tofacitinib, upatacitinib).

Notable Recent Deals

• In February 2019, Mayne Pharma Group Limited announced that they have launched the drug LEXETTE (halobetasol propionate) foam 0.05% in the United States.


• In January 2020, Eli Lilly and Company announced that they have acquired Dermira, which is a biopharmaceutical company engaged in the introduction of novel therapies to treat the chronic skin conditions in a much better way. After this acquisition, the company will expand the pipeline of Lilly's immunology with the addition of lebrikizumab which is a new monoclonal antibody designed to treat atopic dermatitis. This acquisition also expands the company portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium).

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

The COVID-19 pandemic has led to most dermatologists in Australia gaining first-hand experience in teledermatology. Moving forward, hybrid teledermatology seems to be the preferred delivery method, using practical telehealth guidelines created for the Australian context. The results presented here include responses from a significant number of dermatologists who had not used telehealth before. They indicate that teledermatology may be most suited for ongoing care of patients on biologic therapy and with certain inflammatory conditions. For skin checks, specific set ups may be required.

The Australasian College of Dermatologists (ACD) is the peak medical college accredited by the Australian Medical Council for the training and professional development of medical practitioners in the specialty of dermatology. ACD is the leading authority in Australia for dermatology, providing information, advocacy and advice to patients, communities, government and other health stakeholders on skin health and dermatological practice. Medical practitioners who have successfully completed the training program of the ACD are known as Fellows of the College (FACD). Fellows of the College are recognised by the Medical Board of Australia as specialists in dermatology. Dermatologists maintain their professional standards and develop new skills through participation in the Colleges continuing professional development (CPD) program.